Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$40.84+3.9%$37.68$12.30▼$48.40$4.39B0.271.11 million shs1.03 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+3.95%+2.72%-3.45%+29.32%+183.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$40.84+3.9%$37.68$12.30▼$48.40$4.39B0.271.11 million shs1.03 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+3.95%+2.72%-3.45%+29.32%+183.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.82Moderate Buy$48.7519.37% UpsideCurrent Analyst Ratings BreakdownLatest EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026EWTXEdgewise Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.007/17/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026EWTXEdgewise Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.007/6/2026EWTXEdgewise Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $51.006/17/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $59.006/17/2026EWTXEdgewise Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $32.006/16/2026EWTXEdgewise Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.006/16/2026EWTXEdgewise Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/2/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$50.00 ➝ $48.006/2/2026EWTXEdgewise Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $45.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)Latest EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026EWTXEdgewise Therapeutics-$0.48N/AN/AN/AN/AN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A22.6122.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableEWTX HeadlinesRecent News About These CompaniesEdgewise Therapeutics, Inc. $EWTX Shares Sold by Granahan Investment Management LLCJuly 25 at 6:24 AM | marketbeat.comSiren L.L.C. Sells 99,727 Shares of Edgewise Therapeutics, Inc. $EWTXJuly 24 at 6:16 AM | marketbeat.comSEB Asset Management AB Makes New Investment in Edgewise Therapeutics, Inc. $EWTXJuly 22 at 5:04 AM | marketbeat.comEdgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?July 21, 2026 | finance.yahoo.comEdgewise Therapeutics (NASDAQ:EWTX) Trading 5.7% Higher - Time to Buy?July 17, 2026 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 15, 2026 | americanbankingnews.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Moderate Buy" by AnalystsJuly 15, 2026 | marketbeat.comSG Americas Securities LLC Sells 84,919 Shares of Edgewise Therapeutics, Inc. $EWTXJuly 14, 2026 | marketbeat.comServier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy BusinessJuly 13, 2026 | manilatimes.netMEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular PipelineJuly 13, 2026 | prnewswire.comCandriam S.C.A. Sells 53,798 Shares of Edgewise Therapeutics, Inc. $EWTXJuly 13, 2026 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Down 7.1% - Time to Sell?July 10, 2026 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Insider Sells 200,000 Shares of StockJuly 3, 2026 | insidertrades.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesJuly 1, 2026 | prnewswire.comIs Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?June 29, 2026 | insidermonkey.comEdgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial DataJune 26, 2026 | insidermonkey.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy TranscriptJune 17, 2026 | seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - SlideshowJune 17, 2026 | seekingalpha.comWhy Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Down 9.20%June 16, 2026 | aaii.comAEdgewise Therapeutics Reports Improvements In Heart Drug TrialJune 16, 2026 | benzinga.comSpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fallJune 16, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$40.84 +1.55 (+3.95%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$41.30 +0.45 (+1.11%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
